Cargando…
Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry
Lanreotide depot (LD; commercial name Somatuline(®) Depot) is an injectable, extended-release formulation of the synthetic somatostatin analog (SSA) lanreotide. In recent clinical trials, LD was found to be suitable for self or partner administration, avoiding the need to travel to a medical facilit...
Autores principales: | Salvatori, Roberto, Woodmansee, Whitney W., Molitch, Mark, Gordon, Murray B., Lomax, Kathleen G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895214/ https://www.ncbi.nlm.nih.gov/pubmed/23314980 http://dx.doi.org/10.1007/s11102-012-0460-2 |
Ejemplares similares
-
Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly
por: Salvatori, Roberto, et al.
Publicado: (2009) -
Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis
por: Woodmansee, Whitney W., et al.
Publicado: (2018) -
Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective
por: Bevan, J S, et al.
Publicado: (2008) -
Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
por: Bernabéu, Ignacio, et al.
Publicado: (2020) -
Therapeutic options in the management of acromegaly: focus on lanreotide Autogel(®)
por: Roelfsema, Ferdinand, et al.
Publicado: (2008)